Atai Life Sciences N.V. (Nasdaq: ATAI)

ATAI is a biotechnology company founded in 2018 in response to the clear and growing unmet needs of mental health patients worldwide. ATAI is dedicated to acquiring, incubating and efficiently developing innovative therapeutics to treat depression, anxiety, addiction, and other mental health disorders. ATAI's business model combines funding, technology, scientific and regulatory expertise with a focus on psychedelic therapy and other drugs with differentiated safety profiles and therapeutic potential. By pooling resources and best practices, ATAI aims to responsibly accelerate the development of new medicines across its business entities, seeking to effectively treat and ultimately heal mental health disorders. ATAI's mission is to bridge the gap between what the mental healthcare system currently provides and what patients need. ATAI is headquartered in Berlin, with offices in New York and San Diego. *

	Start	2018-07-05 established
	Group	Atai Life Sciences (Group)
	Predecessor	Atai Life Sciences B.V.
	Industry	LIFE SCIENCES
	Industry 2	venture capital
	Person	Brand, Florian (ATAI Life Sciences 202004 CEO)
	Person 2	Angermayer, Christian (Apeiron Investment 202010 Founder formerly Co-founder of Ribopharma)

	Region	Netherlands_oo
	Country	Netherlands
	City	n. a.
		Address record changed: 2021-07-05

Basic data	Employees	n. a.

		* Document for »About Section«: Atai Life Sciences AG. (11/23/20). "Press Release: Atai Life Sciences Announces Closing of $125 Million Series C Financing Round". New York, NY.

		Record changed: 2024-02-12